COLL
Price
$21.93
Change
+$0.05 (+0.23%)
Updated
Oct 7 closing price
Capitalization
736.73M
28 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$17.49
Change
-$0.05 (-0.29%)
Updated
Oct 7 closing price
Capitalization
20.98B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs VTRS

COLL vs VTRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. VTRS commentary
Oct 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Buy and VTRS is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
COLL vs VTRS: Fundamental Ratings
COLL
VTRS
OUTLOOK RATING
1..100
2890
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
13
Undervalued
PROFIT vs RISK RATING
1..100
9346
SMR RATING
1..100
5091
PRICE GROWTH RATING
1..100
8333
P/E GROWTH RATING
1..100
881
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (13) in the null industry is somewhat better than the same rating for COLL (63) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than COLL’s over the last 12 months.

VTRS's Profit vs Risk Rating (46) in the null industry is somewhat better than the same rating for COLL (93) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than COLL’s over the last 12 months.

COLL's SMR Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for VTRS (91) in the null industry. This means that COLL’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (33) in the null industry is somewhat better than the same rating for COLL (83) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than COLL’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for COLL (88) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew significantly faster than COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLVTRS
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
62%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
54%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
67%
MACD
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
52%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
66%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
69%
Bearish Trend 1 day ago
64%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
53%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
69%
COMPARISON
Comparison
Oct 08, 2026
Stock price -- (COLL: $21.93 vs. VTRS: $17.49)
Brand notoriety: COLL and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 78% vs. VTRS: 97%
Market capitalization -- COLL: $736.73M vs. VTRS: $20.98B
COLL [@Pharmaceuticals: Generic] is valued at $736.73M. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $20.98B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green while VTRS’s FA Score has 3 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than COLL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • COLL’s TA Score: 4 bullish, 3 bearish.
  • VTRS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, COLL is a better buy in the short-term than VTRS.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +0.50% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -1.30% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.33%. For the same industry, the average monthly price growth was -4.35%, and the average quarterly price growth was +24.19%.

Reported Earning Dates

COLL is expected to report earnings on Nov 05, 2026.

VTRS is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.33% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
COLL
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASRV4.480.08
+1.82%
AmeriServ Financial
COFS33.090.07
+0.21%
ChoiceOne Financial Services
CLOV4.56-0.04
-0.87%
Clover Health Investments Corp
CLDI1.01-0.01
-0.98%
Calidi Biotherapeutics Inc
AHR49.37-1.12
-2.22%
American Healthcare REIT

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with EBS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then EBS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
+0.23%
EBS - COLL
40%
Loosely correlated
+1.73%
VTRS - COLL
36%
Loosely correlated
-0.29%
AMRX - COLL
35%
Loosely correlated
-3.18%
AMPH - COLL
34%
Loosely correlated
-1.43%
SNDL - COLL
33%
Loosely correlated
+1.63%
More